Abstract: Systems and method for producing a small-scale mixer are provided. In some implementations, a method for includes obtaining dimensions of an at-scale mixer. The method also includes determining first dimensions of the small-scale mixer based on respective dimensions of the at-scale mixer. The method further includes determining second dimensions of the small-scale mixer independent of the dimensions of the at-scale mixer. Additionally, the method includes generating the small-scale mixer using the first dimensions and the second dimensions using a three-dimensional printer.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins.

Abstract: The present application provides methods for predicting freeze-thaw profiles across scales and geometries, producing predetermined freeze-thaw profiles in scaled-down experiments using a computational fluid dynamics model, and using scaled-down freeze-thaw profiles to predict at-scale freeze-thaw profiles.

Abstract: A radio node that selectively performs a remedial action is described. During operation, the radio node detects a potential change in a location of the radio node relative to a predefined location. For example, the radio node may detect the potential change in the location based at least in part on a change in a network parameter of the radio node and/or by performing a scan of wireless signals in an environment of the radio node. Then, in response to detecting the potential change in the location, the radio node determines the location of the radio node (e.g., by using a positioning system). When there is at least a predefined change in the location of the radio node relative to the predefined location, the radio node selectively performs the remedial action. Notably, the remedial action may include: providing an alert or a notification, discontinuing transmissions, or re-register the radio node.

Abstract: An apparatus for activating a physical card in a virtual environment comprises a processor associated with a server. The processor is configured to receive a request to issue a physical card to a first user and to generate a first non-fungible token (NFT) for storage in the physical card, wherein the first NFT is then displayed as a digital card in a virtual environment. The processor is further configured to receive the digital card in an interaction and to generate a second NFT. The processor is further configured to combine the first NFT and the second NFT to generate an activation NFT that allows the physical card to access a profile corresponding to the first user during an interaction. The processor is further configured to transmit the activation NFT and an instruction to the first user device to store the activation NFT in the physical card.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: Apparatus, systems and methods for providing a four-part, virtual reality (VR) customer service interaction between a customer service avatar operating on a VR platform and a customer using both a mobile device and a VR device are provided. Methods may include activating a VR session between the customer service avatar and the customer. Methods may include validating the VR session between the customer service avatar and the customer. Methods may include processing a co-browsing VR session request. Methods may include initiating the VR session between the customer service avatar and the customer.

Abstract: A user device executes a partner application including a partner application module. The module acquires a first set of events associated with user actions in the partner application. The module reports a first subset of the first set of events to a remote computing system. The module refrains from reporting a second subset to the remote system based on satisfaction of initial event capping conditions that indicate which events should not be reported to the remote system. The module receives updated event capping conditions from the remote system that are different than the initial conditions, acquires a second set of events, and reports a first subset of the second set to the remote system. The module refrains from reporting a second subset of the second set to the remote system based on satisfaction of the updated conditions. The remote system reports the first subsets to a partner device.

Abstract: Apparatus, systems and methods for providing a four-part, virtual reality (VR) customer service interaction between a customer service avatar operating on a VR platform and a customer using both a mobile device and a VR device are provided. Methods may include activating a VR session between the customer service avatar and the customer. Methods may include validating the VR session between the customer service avatar and the customer. Methods may include processing a co-browsing VR session request. Methods may include initiating the VR session between the customer service avatar and the customer.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins.